Trial · NCT03845010
Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment
NCT03845010, Not applicable, Completed, Maatschap Cardiologie Zwolle
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment. Trials, record NCT03845010. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03845010
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment
- NCT number
- NCT03845010
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 22 participants, actual
- Lead sponsor
- Maatschap Cardiologie Zwolle
- Conditions
- Ventricular Premature Beats
- Interventions
- Sotalol, Flecainide and verapamil, Catheter ablation
- First posted
- 2019-02-19
- Last updated
- 2023-06-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Successful therapy | After 3 months | Number of patients reaching succesfull therapy defined as \>80% reduction of of VPB/VT burden after 3 months |
| Secondary | VPB/VT burden | 3, 6, 12 months after intervention | |
| Secondary | Change in VPB/VT burden | Before the intervention (baseline) and 3, 6, 12 months after intervention | Measurement in different subgroups e.g.: males, pre and post-menopausal women |
| Secondary | The impact in terms of total Quality of Life | 3, 6, 12 months after intervention compared to baseline (before intervention) | Use of the University of Toronto AF severity scale (AFSS) questionnaire to measure Quality of Life. The total score range is 0-35. Seven questions in total with a maximum score of 5 points per question. |
| Secondary | Association between number of VPB/hour and heart rate (HR)/hour during 24-hours Holter- monitoring | At baseline | A scatterplot will be made in order to depict the association between the number of VBP/hour and heart rate (HR)/hour during 24-hour Holter-monitoring |
| Secondary | Number of pro-arrhythmic effects, (non)-sustained VT or atrial flutter, in AAD arms with frequent visits and use of 24-hour Holter monitoring | 3, 6 and 12 months after intervention | |
| Secondary | QTc prolongation (sotalol) and QRS broadening (flecainide) with requiring frequent checks with standard ECG and/or treadmill test | 4-6 weeks after first administration of AAD | |
| Secondary | Complication rate of catheter ablation | Procedure and 3, 6 and 12 months after intervention | In all patients with special interest to the subgroup of patients with anatomically challenging origin of (non-RVOT) VPB/VTs |
| Secondary | Extended evaluation of left ventricular function with transthoracic echo (TTE) (including global longitudinal strain rate measurement) | Baseline, 6 and 12 months after intervention | |
| Secondary | Absolute and relative difference in VPB/VT burden (%) from baseline, during treatment with sotalol versus treatment with flecainide/verapamil | 3, 6 and 12 months after intervention |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03845010
GET https://conductscience.org/api/trials/v1/NCT03845010/registered